ReviewAdvances in experimental medicine and biology2017
Current Standards of Care and Long Term Outcomes for Thalassemia and Sickle Cell Disease.
Review in Advances in experimental medicine and biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Assessment and Benchmarking of Model Informed Approaches in Drug Development for Hemoglobinopathies: A Review of Scientific Advices From January 2000 to December 2024.CPT: pharmacometrics & systems pharmacology · 2026Review
- Study Designs and Crafting Endpoints for Gene Therapy Development Programs in Rare Disease: A Narrative Review.Advances in therapy · 2026Review
- Self-management for youth and young adults with childhood-onset chronic conditions: A scoping review of health care transition planning literature.Health care transitions · 2026Review
- A New Method for Screening Thalassemia Patients Using Mid-Infrared Spectroscopy.Diagnostics (Basel, Switzerland) · 2025Article
- HELIOS Action: Advancing research, education, and equity in hemoglobinopathies across Europe and beyond.HemaSphere · 2025Article
- Association of depression and hydroxyurea use with neuropathic pain in hemoglobinopathies.Scientific reports · 2025Article
- Complement is activated in patients with acute chest syndrome caused by sickle cell disease and represents a therapeutic target.Science translational medicine · 2025Article
- Comparison of Asymptomatic Brain Lesions Between Thalassemia Major and Sickle Cell Anemia Patients.Medicina (Kaunas, Lithuania) · 2025Article
- Article
- Gene therapies for sickle cell disease: Effectiveness and value.Journal of managed care & specialty pharmacy · 2023Article
- The Effect of Long-Term Iron Chelator Therapy on Serum Levels of Hepcidin and Ferritin in Patients with Thalassemia Major and Intermediate.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2022Article
- Microcytic Anemia: An Insidious Presentation of Sickle Cell Beta+ Thalassemia, a Rare Sickle Cell Variant.Cureus · 2022Article
- Transfusion Complications in Thalassemia: Patient Knowledge and Perspectives.Frontiers in medicine · 2022Article
- Hearing Loss in Beta-Thalassemia: Systematic Review.Journal of clinical medicine · 2021Review
- Sickle Cell Anemia andPathogens (Basel, Switzerland) · 2021Review
- Auditory cortex hypoperfusion: a metabolic hallmark in Beta Thalassemia.Orphanet journal of rare diseases · 2021Article
- Hemoglobinopathies: An update on the prevalence trends in Southern Saudi Arabia.Saudi medical journal · 2021Article
- A multicenter cross-sectional study of the quality of life and iron chelation treatment satisfaction of patients with transfusion-dependent β-thalassemia, in routine care settings in Western Greece.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2021Article
- Healthcare Workers' Knowledge and Resource Availability for Care of Sickle Cell Disease in Dar es Salaam, Tanzania.Frontiers in genetics · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Thalassemia and sickle cell disease (SCD) are disorders of hemoglobin that affect millions of people worldwide. The carrier states for these diseases arose as common, balanced polymorphisms during human history because they afforded protection against severe forms of malaria. These complex, multisystem diseases are reviewed here with a focus on current standards of clinical management and recent research findings. The importance of a comprehensive, multidisciplinary and lifelong system of care is also emphasized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.